PIM1 and non-Hodgkin lymphoma: In addition, most NHLs are susceptible to Pim kinase inhibition either in mono or dual therapy; and the Pim-1 gene is susceptible to somatic hypermutation activity in some NHL subtypes (Fig. 7A).